Emyria Ltd has released a press release.
EMD-RX5 demonstrates excellent safety and bioavailability
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Emyria
- Further positive MDMA analogue screening results received
- Broker Briefing Presentation
- Emyria launches second ultra-pure CBD capsule
- Recruitment commenced for EMD-RX5 Phase 1 Study
- Ethics approval received for EMD-RX5 Phase 1 Study
Later from Emyria
- Emyria expands MDMA analogue program with UWA
- Emyria expands drug candidate library inspired by MDMA
- Appendix 4C - Quarterly
- Preclinical studies initiated for MDMA-inspired analogues
- Emyria receives ethics approval for EMD-RX5 Phase 3 trial
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria